psychedelic therapy – Page 6

Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience

mycolabadmin

This study examined how people describe their experiences with psychedelic drugs by analyzing personal accounts shared online. Researchers found that experiences naturally fall into three phases: preparation (where knowledge and intentions matter), the actual experience (where sensory changes, mindset, and environment shape what happens), and afterward (where lasting behavioral and attitude changes occur). The study highlights how music, nature, supportive people, and clear intentions can help guide psychedelic experiences toward positive, meaningful outcomes.

Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia

mycolabadmin

This Australian study surveyed over 500 people about their views on psychedelics like psilocybin and MDMA for treating mental health conditions. Most people supported medical legalization of these substances, though many had safety concerns. Those with mental illness, those with prior psychedelic experience, and those with better knowledge of psychedelics were most supportive of their therapeutic use.

Lower-dose psycholytic therapy – A neglected approach

mycolabadmin

This review examines psycholytic therapy, a method using lower doses of LSD or psilocybin combined with ongoing psychotherapy to help people process psychological conflicts and trauma. Developed in Europe during the 1960s-1970s and used successfully at over 30 clinics, this approach was largely abandoned when psychedelics became illegal but is now being reconsidered. Historical research shows it was effective for anxiety, depression, and personality issues in treatment-resistant patients, with safety profiles comparable to conventional therapy.

Psilocybin: Systematic review of its use in the treatment of depression

mycolabadmin

Researchers reviewed scientific studies on psilocybin, a psychedelic compound found in certain mushrooms, as a treatment for depression. The studies showed that psilocybin significantly reduced depressive symptoms faster than standard treatments, with minimal side effects. This suggests psilocybin could be a promising new option for people with depression who haven’t benefited from traditional medications.

Mycelium Growth and Development of Psilocybe spp. Mother Cultures on Agar-Based Media

mycolabadmin

This research examines how different growing media affect four types of psilocybin mushrooms. The study found that malt extract agar worked best for some mushroom types while potato-based media worked better for others. Commercial powdered potato media performed poorly, especially for one sensitive strain. These findings help optimize mushroom cultivation for therapeutic and commercial purposes.

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

mycolabadmin

This comprehensive review examines how psychedelic substances, from magic mushrooms to LSD, are being studied as treatments for addiction. After decades of restriction, researchers are rediscovering what indigenous cultures have known for thousands of years: these substances can help people overcome alcohol, drug, and tobacco addiction. The research shows promising results, particularly when combined with therapy, with abstinence rates significantly higher than traditional treatments.

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

This study analyzed the chemical composition of ‘magic mushrooms’ (Psilocybe) at different growth stages—liquid cultures, grain cultures, and mature fruiting bodies. Using advanced laboratory techniques, researchers found that fruiting bodies contain the highest levels of psilocybin (the psychoactive compound), while mycelium contains unique beneficial compounds like alpha-glycerylphosphorylcholine that may have therapeutic value without strong psychedelic effects. The findings suggest that Psilocybe mycelium could be developed as a non-intoxicating health supplement with potential therapeutic applications.

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds

mycolabadmin

Scientists extracted and analyzed psilocybin and psilocin from Psilocybe cubensis mushrooms to develop a medication for treating mental health disorders like depression and anxiety. Using various analytical techniques, they confirmed the extract contained about 3.26% psilocybin and was safe, pure, and stable. The research shows that creating a psilocybin-based medicine from these mushrooms is feasible and could offer a new treatment option for people struggling with mental health issues.

Exploring Psilocybe spp. mycelium and fruiting body chemistry for potential therapeutic compounds

mycolabadmin

Scientists studied magic mushrooms at different growth stages to understand their chemical makeup. They found that mature mushroom caps contain high levels of psilocybin (the psychedelic compound) but the root-like mycelium contains different beneficial compounds like ergothioneine and choline. This suggests mycelium could be developed as a therapeutic product without the psychedelic effects, potentially offering health benefits while avoiding the mind-altering properties.

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis

mycolabadmin

This comprehensive review examined how psilocybin affects thinking and attention. Researchers analyzed 13 studies and found that psilocybin slows down reaction times during tasks requiring focus and decision-making, though accuracy remains relatively stable. The effects increase with higher doses. Understanding these cognitive changes is important for both therapeutic applications and ensuring safe use of psilocybin in research and clinical settings.

Research Keyword: psychedelic therapy